Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?

By Alan S. Go, E. Hylek, Yuchiao Chang, Katherine Phillips, Lori Henault, A. Capra, Nancy G. Jensvold, J. Selby, D. Singer. Journal of the American Medical Association (JAMA), 2003

767 citations recorded by the source corpus.

Subfields: General Health Professions, Pediatrics, Perinatology and Child Health

View Paper: https://www.semanticscholar.org/paper/3eb44eac3480595dd49688cf56b3091ebbbde9fc

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Paulus Kirchhof
2. A. Camm
3. Gerhard Hindricks
4. Ulrich Schotten
5. A. Goette
6. H. Heidbuchel
7. I. Savelieva
8. D. Atar

Citations in the corpus

• The Net Clinical Benefit of Warfarin Anticoagulation in Atrial Fibrillation (2009, methodology): “In addition, these risk factors, as assessed in our cohort, did confer increased risk for thromboembolism, as in previous studies (2).”
• Selecting Patients With Atrial Fibrillation for Anticoagulation: Stroke Risk Stratification in Patients Taking Aspirin (2004, unknown): “Prescribed aspirin 2580 (100) Women 943 (37) Mean age, y (SD) 72 (9) Age 75 y 1003 (39) Hypertension 1188 ( 46 ) SBP 160 mm Hg 645 (25) Heart failure 655 (25) Diabetes mellitus 346 (13) Prior stroke or TIA 566 (22) Prior MI or angina 464 (18)”
• Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). (2010, background): “Such a practice appears to translate to better outcomes in AF patients in routine care.(10,51)”